Challenges in the diagnosis of Parkinson's disease
Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Tolosa, Eduardo [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021transfer abstract |
|---|
| Umfang: |
13 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport - Fang, Jun ELSEVIER, 2014transfer abstract, London |
|---|---|
| Übergeordnetes Werk: |
volume:20 ; year:2021 ; number:5 ; pages:385-397 ; extent:13 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1474-4422(21)00030-2 |
|---|
| Katalog-ID: |
ELV053749618 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV053749618 | ||
| 003 | DE-627 | ||
| 005 | 20230626035304.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1474-4422(21)00030-2 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001368.pica |
| 035 | |a (DE-627)ELV053749618 | ||
| 035 | |a (ELSEVIER)S1474-4422(21)00030-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.17 |2 bkl | ||
| 084 | |a 58.50 |2 bkl | ||
| 084 | |a 43.12 |2 bkl | ||
| 100 | 1 | |a Tolosa, Eduardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Challenges in the diagnosis of Parkinson's disease |
| 264 | 1 | |c 2021transfer abstract | |
| 300 | |a 13 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. | ||
| 520 | |a Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. | ||
| 700 | 1 | |a Garrido, Alicia |4 oth | |
| 700 | 1 | |a Scholz, Sonja W |4 oth | |
| 700 | 1 | |a Poewe, Werner |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Lancet Publ. Group |a Fang, Jun ELSEVIER |t Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |d 2014transfer abstract |g London |w (DE-627)ELV017537959 |
| 773 | 1 | 8 | |g volume:20 |g year:2021 |g number:5 |g pages:385-397 |g extent:13 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1474-4422(21)00030-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_70 | ||
| 936 | b | k | |a 35.17 |j Katalyse |q VZ |
| 936 | b | k | |a 58.50 |j Umwelttechnik: Allgemeines |q VZ |
| 936 | b | k | |a 43.12 |j Umweltchemie |q VZ |
| 951 | |a AR | ||
| 952 | |d 20 |j 2021 |e 5 |h 385-397 |g 13 | ||
| author_variant |
e t et |
|---|---|
| matchkey_str |
tolosaeduardogarridoaliciascholzsonjawpo:2021----:hlegsnhdanssfak |
| hierarchy_sort_str |
2021transfer abstract |
| bklnumber |
35.17 58.50 43.12 |
| publishDate |
2021 |
| allfields |
10.1016/S1474-4422(21)00030-2 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001368.pica (DE-627)ELV053749618 (ELSEVIER)S1474-4422(21)00030-2 DE-627 ger DE-627 rakwb eng 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Tolosa, Eduardo verfasserin aut Challenges in the diagnosis of Parkinson's disease 2021transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. Garrido, Alicia oth Scholz, Sonja W oth Poewe, Werner oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:20 year:2021 number:5 pages:385-397 extent:13 https://doi.org/10.1016/S1474-4422(21)00030-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 20 2021 5 385-397 13 |
| spelling |
10.1016/S1474-4422(21)00030-2 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001368.pica (DE-627)ELV053749618 (ELSEVIER)S1474-4422(21)00030-2 DE-627 ger DE-627 rakwb eng 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Tolosa, Eduardo verfasserin aut Challenges in the diagnosis of Parkinson's disease 2021transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. Garrido, Alicia oth Scholz, Sonja W oth Poewe, Werner oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:20 year:2021 number:5 pages:385-397 extent:13 https://doi.org/10.1016/S1474-4422(21)00030-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 20 2021 5 385-397 13 |
| allfields_unstemmed |
10.1016/S1474-4422(21)00030-2 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001368.pica (DE-627)ELV053749618 (ELSEVIER)S1474-4422(21)00030-2 DE-627 ger DE-627 rakwb eng 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Tolosa, Eduardo verfasserin aut Challenges in the diagnosis of Parkinson's disease 2021transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. Garrido, Alicia oth Scholz, Sonja W oth Poewe, Werner oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:20 year:2021 number:5 pages:385-397 extent:13 https://doi.org/10.1016/S1474-4422(21)00030-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 20 2021 5 385-397 13 |
| allfieldsGer |
10.1016/S1474-4422(21)00030-2 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001368.pica (DE-627)ELV053749618 (ELSEVIER)S1474-4422(21)00030-2 DE-627 ger DE-627 rakwb eng 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Tolosa, Eduardo verfasserin aut Challenges in the diagnosis of Parkinson's disease 2021transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. Garrido, Alicia oth Scholz, Sonja W oth Poewe, Werner oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:20 year:2021 number:5 pages:385-397 extent:13 https://doi.org/10.1016/S1474-4422(21)00030-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 20 2021 5 385-397 13 |
| allfieldsSound |
10.1016/S1474-4422(21)00030-2 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001368.pica (DE-627)ELV053749618 (ELSEVIER)S1474-4422(21)00030-2 DE-627 ger DE-627 rakwb eng 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Tolosa, Eduardo verfasserin aut Challenges in the diagnosis of Parkinson's disease 2021transfer abstract 13 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. Garrido, Alicia oth Scholz, Sonja W oth Poewe, Werner oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:20 year:2021 number:5 pages:385-397 extent:13 https://doi.org/10.1016/S1474-4422(21)00030-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 20 2021 5 385-397 13 |
| language |
English |
| source |
Enthalten in Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport London volume:20 year:2021 number:5 pages:385-397 extent:13 |
| sourceStr |
Enthalten in Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport London volume:20 year:2021 number:5 pages:385-397 extent:13 |
| format_phy_str_mv |
Article |
| bklname |
Katalyse Umwelttechnik: Allgemeines Umweltchemie |
| institution |
findex.gbv.de |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| authorswithroles_txt_mv |
Tolosa, Eduardo @@aut@@ Garrido, Alicia @@oth@@ Scholz, Sonja W @@oth@@ Poewe, Werner @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV017537959 |
| dewey-sort |
3570 |
| id |
ELV053749618 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV053749618</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626035304.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1474-4422(21)00030-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001368.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV053749618</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1474-4422(21)00030-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.17</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.50</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tolosa, Eduardo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Challenges in the diagnosis of Parkinson's disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garrido, Alicia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scholz, Sonja W</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Poewe, Werner</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Lancet Publ. Group</subfield><subfield code="a">Fang, Jun ELSEVIER</subfield><subfield code="t">Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV017537959</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:385-397</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1474-4422(21)00030-2</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.17</subfield><subfield code="j">Katalyse</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.50</subfield><subfield code="j">Umwelttechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2021</subfield><subfield code="e">5</subfield><subfield code="h">385-397</subfield><subfield code="g">13</subfield></datafield></record></collection>
|
| author |
Tolosa, Eduardo |
| spellingShingle |
Tolosa, Eduardo ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 Challenges in the diagnosis of Parkinson's disease |
| authorStr |
Tolosa, Eduardo |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV017537959 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Challenges in the diagnosis of Parkinson's disease |
| topic |
ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| topic_unstemmed |
ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| topic_browse |
ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a g ag s w s sw sws w p wp |
| hierarchy_parent_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| hierarchy_parent_id |
ELV017537959 |
| dewey-tens |
570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV017537959 |
| title |
Challenges in the diagnosis of Parkinson's disease |
| ctrlnum |
(DE-627)ELV053749618 (ELSEVIER)S1474-4422(21)00030-2 |
| title_full |
Challenges in the diagnosis of Parkinson's disease |
| author_sort |
Tolosa, Eduardo |
| journal |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| journalStr |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
385 |
| author_browse |
Tolosa, Eduardo |
| container_volume |
20 |
| physical |
13 |
| class |
570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Tolosa, Eduardo |
| doi_str_mv |
10.1016/S1474-4422(21)00030-2 |
| dewey-full |
570 540 |
| title_sort |
challenges in the diagnosis of parkinson's disease |
| title_auth |
Challenges in the diagnosis of Parkinson's disease |
| abstract |
Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. |
| abstractGer |
Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. |
| abstract_unstemmed |
Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 |
| container_issue |
5 |
| title_short |
Challenges in the diagnosis of Parkinson's disease |
| url |
https://doi.org/10.1016/S1474-4422(21)00030-2 |
| remote_bool |
true |
| author2 |
Garrido, Alicia Scholz, Sonja W Poewe, Werner |
| author2Str |
Garrido, Alicia Scholz, Sonja W Poewe, Werner |
| ppnlink |
ELV017537959 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/S1474-4422(21)00030-2 |
| up_date |
2024-07-06T19:48:40.162Z |
| _version_ |
1803860385636286464 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV053749618</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626035304.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1474-4422(21)00030-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001368.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV053749618</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1474-4422(21)00030-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.17</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.50</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tolosa, Eduardo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Challenges in the diagnosis of Parkinson's disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">13</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Parkinson's disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson's disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson's disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson's disease. Substantial progress has been made in the development of diagnostic biomarkers, and genetic and imaging tests are already part of routine protocols in clinical practice, while novel tissue and fluid markers are under investigation. Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garrido, Alicia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scholz, Sonja W</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Poewe, Werner</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Lancet Publ. Group</subfield><subfield code="a">Fang, Jun ELSEVIER</subfield><subfield code="t">Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV017537959</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:385-397</subfield><subfield code="g">extent:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1474-4422(21)00030-2</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.17</subfield><subfield code="j">Katalyse</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.50</subfield><subfield code="j">Umwelttechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2021</subfield><subfield code="e">5</subfield><subfield code="h">385-397</subfield><subfield code="g">13</subfield></datafield></record></collection>
|
| score |
7.399967 |